Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.45 |
| ▸ | TFPI | P10646 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | TSG101 | Q99816 | 6/20 | 0.42 |
| ▸ | VDR | P11473 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.40 |
| ▸ | KRAS | P01116 | 2/20 | 0.39 |
| ▸ | HRAS | P01112 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25888213 | 0.97 | ESR1 (0.49) | ESR1MDM2TFPIPGRESR2 | |
| SCHEMBL28564330 | 0.75 | ALB (0.52) | ESR1MDM2PGRESR2VDR | |
| SCHEMBL31065620 | 0.75 | ALB (0.52) | ESR1MDM2PGRESR2VDR | |
| SCHEMBL13656609 | 0.73 | IL23R (0.43) | ESR1ALBIL23R | |
| SCHEMBL14571381 | 0.73 | BACE1 (0.39) | ESR1 | |
| SCHEMBL14571387 | 0.72 | FOLH1 (0.39) | ESR1MDM2TFPIALB | |
| SCHEMBL314241 | 0.71 | ALB (0.51) | ALB | |
| SCHEMBL13748088 | 0.70 | ESR1 (0.45) | ESR1PGRESR2TSG101VDR | |
| SCHEMBL15061131 | 0.70 | ESR1 (0.45) | ESR1PGRESR2TSG101VDR | |
| SCHEMBL10168630 | 0.69 | RXFP1 (0.54) | TFPIRXFP1KRASHRASSOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234971-A1 | 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors | ABBVIE INC. (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234971-A1 | 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors | BCL9L, BCL2L1, BCL2L2 | ESR1 3502/4885MDM2 974/4885TFPI 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.